Metraipolis › archive › dc_3d69e481fcc1
Optimizing vedolizumab therapy in ulcerative colitis: A critical synthesis of trial evidence and the emerging role of artificial intelligence — Europe PMC PMID:41642870
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41642870
- DOI
- 10.1371/journal.pdig.0001208
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-07T17:20:46.075Z
- SHA-256 of the archived text
584f1e8c4e55718f99230fac8f9b3deb7add627bcd5c1481d6212800ff7cc792- Stable URL of this page
https://metraipolis.com/documento/dc_3d69e481fcc1
How to cite
Optimizing vedolizumab therapy in ulcerative colitis: A critical synthesis of trial evidence and the emerging role of artificial intelligence — Europe PMC PMID:41642870 — Europe PMC (en), https://europepmc.org/article/MED/41642870 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_3d69e481fcc1 (Metraipolis archive dc_3d69e481fcc1, sha256 584f1e8c4e55718f99230fac8f9b3deb7add627bcd5c1481d6212800ff7cc792)
BibTeX
@misc{dc3d69e481fcc1,
title = {Optimizing vedolizumab therapy in ulcerative colitis: A critical synthesis of trial evidence and the emerging role of artificial intelligence — Europe PMC PMID:41642870},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41642870},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_3d69e481fcc1; sha256 584f1e8c4e55718f99230fac8f9b3deb7add627bcd5c1481d6212800ff7cc792},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41642870. Agents can read the archived copy with the MCP tool read_document.